MammaPrint was the only test to predict significant 36% and 52% reductions in DFS and BCFI events, respectively, for patients treated with extended endocrine therapy MammaPrint testing for endocrine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results